Pear: Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst

 

• Interim results from the DREAM trial showed treatment with Somryst, a prescription digital therapeutic (PDT) for patients with chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity through six months1

• New real-world data are consistent with the clinical effects previously observed in pivotal clinical trials for Somryst, the only FDA-authorized PDT to treat chronic insomnia

https://www.businesswire.com/news/home/20220608005412/en/Pear-Presents-Interim-Real-World-Data-Showing-Significant-Reductions-in-Symptoms-of-Chronic-Insomnia-Anxiety-and-Depression-with-Somryst%C2%AE-at-SLEEP-2022